通过共价逆agonist FX-909 进行PPARγ介导的转录抑制的结构基础
Zane T Laughlin1, Liudmyla Arifova1,2, Paola Munoz-Tello1
1Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
新型药物FX-909通过向氧酶增殖器激活受体玛 (PPARγ) 有效地抑制膀癌. 与较旧的化合物相比,这种共价逆agonist表现出比较高的PPARγ活性抑制.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
背景情况:
- 过酶增殖器激活受体玛 (PPARγ) 过度激活可促进尿路细胞 (膀) 癌症的生长.
- 抑制PPARγ活性的化合物为膀癌提供了治疗策略.
研究的目的:
- 为了比较FX-909,一种共价PPARγ逆agonist的作用机制,与其他相关化合物.
- 为了阐明FX-909改进的PPARγ反向激进的结构基础.
主要方法:
- 使用功能分析和核磁共振 (NMR) 研究.
- 用FX-909和一个核心压缩复合的PPARγ联体结合域 (LBD) 的晶体结构确定.
主要成果:
- 与T0070907.7相比,FX-909表现出增强的核心压力选择性反向激励机制.
- FX-909更有效地稳定了一种转录抑制的PPARγ LBD形态.
- 晶体结构揭示了共价逆agonists之间共享的压制性构造.
结论:
- FX-909代表了一种药理学上显著和临床上相关的PPARγ逆agonist.
- 这些发现强调了转录抑制PPARγ逆agonists在膀癌中的治疗潜力.
更多相关视频
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
相关概念视频
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Master Transcription Regulators
Cooperative Binding of Transcription Regulators
RNA Polymerase II Accessory Proteins
